Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy (vol 22, pg 603, 2020)

导出原文传递

翻译打印收藏纠错

作者： Passaro, A. ^[1] ; Mancuso, P. ^[2] ; Gandini, S. ^[3] ; Spitaleri, G. ^[4] ; Labanca, V. ; Guerini-Rocco, E. ; Barberis, M. ; Catania, C. ; Del Signore, E. ; de Marinis, F. ; Bertolini, F.

作者单位： European Inst Oncol IRCCS, IEO, Div Epidemiol & Biostat, Milan, Italy ^[1] European Inst Oncol IRCCS, IEO, Lab Hematol Oncol, Milan, Italy ^[2] European Inst Oncol IRCCS, IEO, Div Thorac Oncol, Via G Ripamonti 435, I-20141 Milan, Italy ^[3] European Inst Oncol IRCCS, IEO, Div Pathol & Lab Med, Milan, Italy ^[4]

发布时间 2021-02-08

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

Clinical & translational oncology

2020年22卷4期

621-621页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy (vol 22, pg 603, 2020)

Clinical & translational oncology

相似文献

Clinical & translational oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy (vol 22, pg 603, 2020)

Clinical & translational oncology

相似文献

Clinical & translational oncology

相关期刊

检索历史清除